Abstract
Original language | English |
---|---|
Pages (from-to) | 619-634 |
Number of pages | 16 |
Journal | Diabetes Therapy |
Volume | 13 |
Issue number | 4 |
Early online date | 2022 |
DOIs | |
Publication status | Published - 1 Apr 2022 |
Keywords
- Antidiabetic drug
- Glycaemic control
- Insulin therapy
- Primary care
- Type 2 diabetes
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Diabetes Therapy, Vol. 13, No. 4, 01.04.2022, p. 619-634.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes
AU - Jude, Edward B.
AU - Malecki, Maciej T.
AU - Gomez Huelgas, Ricardo
AU - Prazny, Martin
AU - Snoek, Frank
AU - Tankova, Tsvetalina
AU - Giugliano, Dario
AU - Khunti, Kamlesh
N1 - Funding Information: Editorial assistance, organisation of the 2-day consensus group meeting and the journal’s Rapid Service Fee were funded by Sanofi. The authors did not receive payment for their contribution to the manuscript. Funding Information: Editorial assistance, organisation of the 2-day consensus group meeting and the journal?s Rapid Service Fee were funded by Sanofi. The authors did not receive payment for their contribution to the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Edward Jude, Maciej Malecki, Ricardo Gomez Huelgas, Martin Prazny, Frank Snoek, Tsvetalina Tankova, Dario Giugliano and Kamlesh Khunti all contributed to the study conception and design, material preparation, data collection and analysis. The first draft of the manuscript was written by Edward Jude, Maciej Malecki, Ricardo Gomez Huelgas, Martin Prazny, Frank Snoek, Tsvetalina Tankova, Dario Giugliano and Kamlesh Khunti, in addition to commenting on previous versions and approving the final manuscript. Medical writing assistance in the preparation of this article was provided by Katie Musialowski, PhD, Aneela Majid, PhD, and Alex Goonesinghe, PhD, from Lucid Group Communications Ltd, First Floor, Jubilee House, Third Avenue, Globe Park, Marlow, Buckinghamshire, SL7 1EY, UK. Dario Giugliano has received honoraria for speaking at meetings from Novartis, Sanofi, Eli Lilly and Company, AstraZeneca, and Novo Nordisk. Edward Jude has served on advisory boards and as speaker or received grants from AstraZeneca, Boehringer Ingelheim, Menarini, Novo Nordisk, Roche and Sanofi. Frank Snoek has served on advisory boards and as speaker or received grants from Sanofi, Abbott, Eli Lilly, Novo Nordisk and Roche. Kamlesh Khunti has acted as a consultant, speaker or received grants for investigator-initiated studies for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and MSD, Boehringer Ingelheim, Bayer, Berlin-Chemie AG/Menarini Group, Janssen, and Napp. Kamlesh Khunti is also supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). Martin Prazny served as a consultant and speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Medtronic, and Teva. Maciej Malecki has acted as a consultant or speaker for AstraZeneca, Bayer, Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Boehringer Ingelheim, Mundipharma, Abbott, Dexcom, and Medtronic. Maciej Malecki also participates in the National Center for Research and Development CRACoV-HHS project (contract number?SZPITALE-JEDNOIMIENNE/18/2020). Ricardo Gomez Huelgas has served on advisory boards and acted as a consultant or speaker or received grants for AstraZeneca, Boehringer-Lilly, Janssen, MSD, Novo Nordisk, Novartis and Sanofi. Tsvetalina Tankova has served on advisory boards and as a speaker for Sanofi, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novo Nordisk, Novartis, MSD and Servier. The opinions and patient profiles represent the opinions of the experts and not Sanofi. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Funding Information: Dario Giugliano has received honoraria for speaking at meetings from Novartis, Sanofi, Eli Lilly and Company, AstraZeneca, and Novo Nordisk. Edward Jude has served on advisory boards and as speaker or received grants from AstraZeneca, Boehringer Ingelheim, Menarini, Novo Nordisk, Roche and Sanofi. Frank Snoek has served on advisory boards and as speaker or received grants from Sanofi, Abbott, Eli Lilly, Novo Nordisk and Roche. Kamlesh Khunti has acted as a consultant, speaker or received grants for investigator-initiated studies for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and MSD, Boehringer Ingelheim, Bayer, Berlin-Chemie AG/Menarini Group, Janssen, and Napp. Kamlesh Khunti is also supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). Martin Prazny served as a consultant and speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Medtronic, and Teva. Maciej Malecki has acted as a consultant or speaker for AstraZeneca, Bayer, Novo Nordisk, Sanofi-Aventis, Lilly, Merck, Boehringer Ingelheim, Mundipharma, Abbott, Dexcom, and Medtronic. Maciej Malecki also participates in the National Center for Research and Development CRACoV-HHS project (contract number—SZPITALE-JEDNOIMIENNE/18/2020). Ricardo Gomez Huelgas has served on advisory boards and acted as a consultant or speaker or received grants for AstraZeneca, Boehringer-Lilly, Janssen, MSD, Novo Nordisk, Novartis and Sanofi. Tsvetalina Tankova has served on advisory boards and as a speaker for Sanofi, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novo Nordisk, Novartis, MSD and Servier. The opinions and patient profiles represent the opinions of the experts and not Sanofi. Publisher Copyright: © 2022, The Author(s).
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Given the progressive nature of type 2 diabetes (T2D), most individuals with the disease will ultimately undergo treatment intensification. This usually involves the stepwise addition of a new glucose-lowering agent or switching to a more complex insulin regimen. However, complex treatment regimens can result in an increased risk of hypoglycaemia and high treatment burden, which may impact negatively on both therapeutic adherence and overall quality of life. Individuals with good glycaemic control may also be overtreated with unnecessarily complex regimens. Treatment simplification aims to reduce individual treatment burden, without compromising therapeutic effectiveness or safety. Despite data showing that simplifying therapy can achieve good glycaemic control without negatively impacting on treatment efficacy or safety, it is not always implemented in clinical practice. Current clinical guidelines focus on treatment intensification, rather than simplification. Where simplification is recommended, clear guidance is lacking and mostly focused on treatment of the elderly. An expert, multidisciplinary panel evaluated the current treatment landscape with respect to guidance, published evidence, recommendations and approaches regarding simplification of complex insulin regimens. This article outlines the benefits of treatment simplification and provides practical recommendations on simplifying complex insulin treatment strategies in people with T2D using illustrative cases.
AB - Given the progressive nature of type 2 diabetes (T2D), most individuals with the disease will ultimately undergo treatment intensification. This usually involves the stepwise addition of a new glucose-lowering agent or switching to a more complex insulin regimen. However, complex treatment regimens can result in an increased risk of hypoglycaemia and high treatment burden, which may impact negatively on both therapeutic adherence and overall quality of life. Individuals with good glycaemic control may also be overtreated with unnecessarily complex regimens. Treatment simplification aims to reduce individual treatment burden, without compromising therapeutic effectiveness or safety. Despite data showing that simplifying therapy can achieve good glycaemic control without negatively impacting on treatment efficacy or safety, it is not always implemented in clinical practice. Current clinical guidelines focus on treatment intensification, rather than simplification. Where simplification is recommended, clear guidance is lacking and mostly focused on treatment of the elderly. An expert, multidisciplinary panel evaluated the current treatment landscape with respect to guidance, published evidence, recommendations and approaches regarding simplification of complex insulin regimens. This article outlines the benefits of treatment simplification and provides practical recommendations on simplifying complex insulin treatment strategies in people with T2D using illustrative cases.
KW - Antidiabetic drug
KW - Glycaemic control
KW - Insulin therapy
KW - Primary care
KW - Type 2 diabetes
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85126070481&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/35274219
UR - http://www.scopus.com/inward/record.url?scp=85126070481&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s13300-022-01222-2
DO - https://doi.org/10.1007/s13300-022-01222-2
M3 - Review article
C2 - 35274219
SN - 1869-6953
VL - 13
SP - 619
EP - 634
JO - Diabetes Therapy
JF - Diabetes Therapy
IS - 4
ER -